drugset / Trial / NCT00978029

Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081)

NCT00978029

Phase 2 Completed 203 enrolled ALK-Abelló A/S
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study was to assess the safety and tolerability of a ragweed allergy immunotherapy tablet (AIT) administered sublingually (under-the tongue) in subjects 50 years of age and older with ragweed-induced rhinoconjunctivitis, with or without asthma.

Timeline

Start
2009-11
Primary completion
2010-02
Completion
2010-02

Drugs

EvaluationDrugModalityDoseRoute
Subject SCH 39641 Unknown 6 unknown Other
Subject SCH 39641 Unknown 12 unknown Other